Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ART-123 Asahi Kasei.

Sascha Khorchidi¹, Ruediger Bantleon, Rainer Kehlbach

¹Department of Radiology, University of Tübingen, Germany. sascha.khorchidi@uni-tuebingen.de

Current Opinion in Investigational Drugs (London, England : 2000)

|September 5, 2002

Summary

Asahi Kasei is developing recombinant thrombomodulin (ART-123) to treat blood clotting disorders. This protein therapy has advanced to Phase III clinical trials for potential thromboembolism treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Five-Year Outcomes of Paclitaxel-Coated Balloons in Patients with Diabetes from the BIOLUX P-III Single-Arm Study.

Vascular health and risk management·2026

Same author

Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial.

Journal of the American College of Cardiology·2026

Same author

Low-dose versus high-dose drug-coated balloons for femoropopliteal lesions: 5-year results from the prospective, randomised COMPARE trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026

Same author

Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Disrupt PAD III Observational Study.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2024

Same author

Outcomes of drug-coated balloon angioplasty in patients with dyslipidemia in the BIOLUX P-III registry: A subgroup analysis.

Vascular·2024

Same author

Erratum: Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.

Journal of the Society for Cardiovascular Angiography & Interventions·2024

Area of Science:

Biotechnology and Pharmaceutical Development
Hematology and Thrombosis Research

Background:

Thromboembolism and disseminated intravascular coagulation are serious blood clotting disorders.
Thrombomodulin is a protein with anticoagulant and cytoprotective properties.
Developing effective therapeutic agents for these conditions remains a critical medical need.

Purpose of the Study:

To evaluate the efficacy and safety of recombinant thrombomodulin (ART-123) for treating thromboembolic disorders.
To explore the therapeutic potential of ART-123 in managing blood clotting abnormalities.

Main Methods:

Development of ART-123, a human recombinant thrombomodulin.
Conducting Phase III clinical trials to assess therapeutic outcomes.
Utilizing a patented composition comprising thrombomodulin for potential liver injury treatment.

Related Experiment Videos

Main Results:

ART-123 exhibits both thrombin inhibiting and protein C stimulating activities.
The drug candidate had progressed to Phase III clinical trials by September 2000.
A patent was granted for a thrombomodulin-based method to treat liver injury.

Conclusions:

Recombinant thrombomodulin (ART-123) shows promise as a therapeutic agent for thromboembolism.
Further clinical evaluation is ongoing to establish its role in treating blood clotting disorders.
Thrombomodulin-based therapies may offer new avenues for managing liver injury.